Patents by Inventor Michael Barry Gravestock
Michael Barry Gravestock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8399489Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.Type: GrantFiled: February 16, 2006Date of Patent: March 19, 2013Assignee: Astrazeneca ABInventors: Gregory Basarab, Brian Dangel, Paul Robert Fleming, Michael Barry Gravestock, Oluyinka Green, Sheila Irene Hauck, Pamela Hill, Kenneth Gregory Hull, George Mullen, Haihong Ni, Brian Sherer, Fei Zhou
-
Publication number: 20100179150Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.Type: ApplicationFiled: February 16, 2006Publication date: July 15, 2010Applicant: ASTRAZENECA ABInventors: Gregory Basarab, Brian Dangel, Paul Robert Fleming, Michael Barry Gravestock, Oluyinka Green, Sheila Irene Hauck, Pamela Hill, Kenneth Gregory Hull, George Mullen, Brian Sherer, Fei Zhou, Haihong Ni
-
Publication number: 20100137243Abstract: Compounds of Formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, and compounds as shown in Formula (I) wherein C is for example (D), (E), (F); wherein A and B are independently selected from (i) and (ii); R2a to R3b are independently selected from hydrogen and fluorine; R1a and R1b are independently selected from, for example, hydroxy, —NHC(?W)R4, (a) and (b); wherein W is O or S; R4 is, for example, hydrogen, amino, (1-4C)alkyl; HET-1 is, for example, a C-linked 5-membered heteroaryl ring; HET-2 is, for example, an N-linked 5-membered, fully or partially unsaturated heterocyclic ring; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.Type: ApplicationFiled: May 28, 2008Publication date: June 3, 2010Applicant: AstraZeneca ABInventors: Michael Barry Gravestock, Neil James Hales, Michael Lingrad Swaim, Sheila Irene Hauck, Stuart Dennett Mills
-
Patent number: 7498350Abstract: A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof: Wherein C is selected from (D) and (E), R2a, R6a, and R3a are independently selected from for example H, CF3, Me and Et; R2b and R6b are independently selected from for example H, F, CF3, Me and Et; R1b is for example optionally substituted diazolyl, triazolyl or tetrazolyl; R4 is for example an optionally substituted 5- or 6-membered heterocyclic ring system. Methods for making compounds of the formula (I), compositions containing them and their use as antibacterial agents are also described.Type: GrantFiled: November 24, 2003Date of Patent: March 3, 2009Assignee: AstraZeneca ABInventors: Michael Barry Gravestock, Neil James Hales, Folkert Reck, Fei Zhou
-
Patent number: 7473699Abstract: Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein —N-HET is, for example, (Ic) or (If) wherein R1 is (1-4C)alkyl; Q is selected from, for example, Q1 wherein R2 and R3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, wherein m is 0, 1 or 2; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.Type: GrantFiled: February 25, 2003Date of Patent: January 6, 2009Assignee: AstraZeneca ABInventors: Michael Barry Gravestock, Neil James Hales, Folkert Reck, Fei Zhou, Paul Robert Fleming, Daniel Robert Carcanague, Marc Michel Girardot
-
Publication number: 20080269214Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are described: Formula (I). Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.Type: ApplicationFiled: March 2, 2006Publication date: October 30, 2008Applicant: ASTRAZENECA ABInventors: Gregory Steven Basarab, Michael Barry Gravestock, Sheila Irene Hauck
-
Patent number: 7396847Abstract: Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, and compounds as shown in (I) wherein C is for example wherein A and B are independently selected from R2a to R3b are independently selected from hydrogen and fluorine; R1a and R1b are independently selected from, for example, hydroxy, —NHC(?W)R4, wherein W is O or S; R4 is, for example, hydrogen, amino, (1-4C)alkyl; HET-1 is, for example, a C-linked 5-membered heteroaryl ring; HET-2 is, for example, an N-linked 5-membered, fully or partially unsaturated heterocyclic ring; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.Type: GrantFiled: September 9, 2002Date of Patent: July 8, 2008Assignee: AstraZeneca ABInventors: Michael Barry Gravestock, Neil James Hales, Michael Lingard Swain, Sheila Irene Hauck, Stuart Dennett Mills
-
Publication number: 20080064689Abstract: Compounds of the formula (I): or a pharmaceutically-acceptable salt or pro-drug thereof: wherein R1 is selected for example from hydrogen, halogen, optionally substituted methyl; R2 and R3 are independently selected from hydrogen, fluoro, chloro and trifluoromethyl; R4 and R5 are independently selected, for example, from hydrogen, methyl, optionally substituted (2-4C)alkyl, C(O)R6 or R4 and R5 together with the nitrogen to which they are attached form an optionally substituted 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring or an optionally substituted imidazole ring. Methods for making the compounds of formula (I), compositions containing them and their use as antibacterial agents are also described.Type: ApplicationFiled: May 24, 2004Publication date: March 13, 2008Applicant: AstraZeneca ABInventors: Daniel Robert Carcanague, Michael Barry Gravestock
-
Patent number: 7199143Abstract: Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein —N-HET is, for example, (Ic) or (If) wherein R1 is, for example, halogen or a (1–4C)alkyl group which is substituted by one substituent selected from, for example, hydroxy, (1–4C)alkoxy, amino, cyano or azido; Q is selected from, for example, Q1 wherein R2 and R3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, wherein m is 0, 1 or 2; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.Type: GrantFiled: February 25, 2003Date of Patent: April 3, 2007Assignee: AstraZeneca ABInventors: Michael Barry Gravestock, Neil James Hales, Folkert Reck, Fei Zhou, Paul Robert Fleming, Daniel Robert Carcanague
-
Patent number: 7192974Abstract: Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, (I) R1a is NH(C?W)R5 or (a); W is O or S; R2 and R3 are for example H or F; R1 is for example hydrogen, or halogen; R5 is selected from hydrogen, (2–6C)alkyl (optionally substituted); R6 and R7 are independently selected from hydrogen, and (1–4C)alkyl (optionally substituted); wherein R4 is either a hydroxymethyl substituent on C-4? of the isoxazoline ring; or R4 is a hydroxymethyl substituent on C-5? of the isoxazoline ring and the stereochemistry at C-5? of the isoxazoline ring and at C-5 of the oxazolidinone ring is selected, such that the compound of formula (I) is a single diastereomer; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are describedType: GrantFiled: February 24, 2004Date of Patent: March 20, 2007Assignee: AstraZeneca ABInventors: Michael Barry Gravestock, Daniel Robert Carcanague, Neil James Hales
-
Patent number: 7186738Abstract: Compounds of the formula (I), or a pharmaceutically-acceptable salts, or in-vivo-hydrolysable esters thereo Formula (I): wherein N-HeT is for example triazolyl; Q is for example phenyl or pyridyl, substituted with: T is for example selected from (TAa1 to TAa12) such as (TAa1) and (TAa5): R4h, R5h, R6h are for example selected from hydrogen, (1–4C)alkyl, (1–4C)alkoxy-carbonyl, (1–4C)alkanoyl and carbamoyl; processes for making them, compositions containing them and their use as antibacterial agents are described.Type: GrantFiled: March 16, 2004Date of Patent: March 6, 2007Assignee: AstraZeneca ABInventors: Michael Barry Gravestock, Neil James Hale, Sheila Irene Hauck
-
Patent number: 7157482Abstract: Compounds of the formula (I), or a pharmaceutically-acceptable salts, or in-vivo-hydrolysable esters thereof, wherein: N—HET is for example triazolyl substituted with R1; R1 is for example optionally substituted (1-4C)alkyl; Q is for example phenyl or pyridyl, substituted with T; T is for example selected from (TAa1 to TAa12) such as (TAa1 and TAa5); formula (II): R4h, R5h, R6h are for example selected from hydrogen, (1-4C)alkyl, (1-4C)alkoxycarbonyl, (1-4C)alkanoyl and carbamoyl; processes for making them, compositions containing them and their use as antibacterial agents are described.Type: GrantFiled: March 16, 2004Date of Patent: January 2, 2007Assignee: AstraZeneca ABInventors: Michael Barry Gravestock, Neil James Hale, Sheila Irene Hauck
-
Patent number: 7141583Abstract: Compounds of the formula (I), or a pharmaceutically acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein HET is an N-linked 5-membered heteroaryl ring, optionally substituted on a C atom by an oxo or thioxo group; and/or by 1 or 2 (1–4C)alkyl groups; and/or on an available nitrogen atom by (1–4C)alkyl; or HET is an N-linked 6-membered heteroaryl ring containing up to three nitrogen heteroatoms in total, optionally substituted on a C atom as above; Q is selected from, for example, Q1 R2 and R3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, of formula (TC5) wherein Rc is, for example, R13CO—, R13SO2— or R13CS—; wherein R13 is, for example, optionally substituted (1–10C)alkyl or R14C(O)O(1–6C)alkyl wherein R14 is optionally substituted (1–10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.Type: GrantFiled: April 23, 2001Date of Patent: November 28, 2006Assignee: AstraZeneca ABInventors: Michael Barry Gravestock, Michael John Betts, Ian Richard Matthews, David Alan Griffin
-
Patent number: 7087629Abstract: Compounds of formula (I) or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein, for example, HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, Q3 and Q5; R2 and R3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N-linked (fully unsaturated) 5-membered heteroaryl ring system or a group of formula (TC5): wherein Rc is, for example, R13CO—, R13SO2— or R13CS—; wherein R13 is, for example, optionally substituted (1–10C)alkyl or R14C(O)O(1–6C)alkyl wherein R14 is optionally substituted (1–10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.Type: GrantFiled: March 6, 2003Date of Patent: August 8, 2006Assignee: AstraZeneca ABInventor: Michael Barry Gravestock
-
Patent number: 7081538Abstract: Compounds of formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein, for example, X is O, S or NH; HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, Q1 and Q2: R2 and R3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N-linked (fully unsaturated) 5-membered heteroaryl ring system or a group of formula (TC5): wherein Rc is, for example, R13CO—, R13SO2— or R13CS—; wherein R13 is, for example, optionally substituted (1–10C)alkyl or R14C(O)O(1–6C)alkyl wherein R14 is optionally substituted (1–10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are describedType: GrantFiled: November 28, 2000Date of Patent: July 25, 2006Assignee: AstraZeneca ABInventors: Michael Barry Gravestock, Michael John Betts
-
Patent number: 6734200Abstract: Compounds of formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolyzable ester thereof, wherein, for example, HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, Q1 and Q2: R2 and R3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N-linked (fully unsaturated) 5-membered heteroaryl ring system or a group of formula (TC5): wherein Rc is, for example, R13CO—, R13SO2— or R13CS—; wherein R13 is, for example, optionally substituted (1-10C)alkyl or R14C(O)O(1-6C)alkyl wherein R14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.Type: GrantFiled: April 5, 2001Date of Patent: May 11, 2004Assignee: AstraZeneca ABInventor: Michael Barry Gravestock
-
Publication number: 20030216373Abstract: Compounds of the formula (I), or a pharmaceutically acceptable salt, or an in-vivo-hydrolysable ester thereof, 1Type: ApplicationFiled: May 6, 2003Publication date: November 20, 2003Inventors: Michael Barry Gravestock, Michael John Betts, Ian Richard Matthews, David Alan Griffin
-
Publication number: 20030216374Abstract: The invention concerns a compound of formula (I): 1Type: ApplicationFiled: April 15, 2003Publication date: November 20, 2003Applicant: Syngenta LimitedInventor: Michael Barry Gravestock
-
Publication number: 20030207899Abstract: Compounds of formula (I) 1Type: ApplicationFiled: March 6, 2003Publication date: November 6, 2003Applicant: AstraZeneca ABInventor: Michael Barry Gravestock
-
Patent number: 6638955Abstract: The present application discloses a class of antibiotic compounds containing an oxazolidinone ring. These compounds have useful activity against Gram-positive pathogens including MRSA and MRCNS and, in particular, against various strains exhibiting resistance to vancomycin and against E. faecium strains resistant to both aminoglycosides and clinically used &bgr;-lactams. The compounds also possess a favorable toxicological profile. This invention further relates to processes for their preparation, to intermediates useful in their preparation, to their use as therapeutic agents and to pharmaceutical compositions containing them.Type: GrantFiled: December 21, 2001Date of Patent: October 28, 2003Assignee: Syngenta LimitedInventor: Michael Barry Gravestock